We searched MEDLINE, Embase, and the Cochrane Library for prospective studies and systematic reviews published in English between Jan 1, 2015, and March 31, 2021, using combinations of the following terms: “deep vein thrombosis”, “pulmonary embolism”, “venous thromboembolism”, “epidemiology”, “pathophysiology”, “diagnosis”, “treatment”, and “prevention”. We also searched CLOT+, a continuously updated repository of pre-appraised, best evidence to support practising physicians in clinical
SeminarVenous thromboembolism
Introduction
Venous thromboembolism includes deep vein thrombosis and pulmonary embolism. Deep vein thrombosis most often occurs in the leg vein but can also develop in the splanchnic, cerebral, and arm veins. In this Seminar, we focus on recent (past 5 years) advances in epidemiology, pathophysiology, diagnosis, treatment, and prevention of deep vein thrombosis of the legs and pulmonary embolism. Future directions are also discussed.
Section snippets
Epidemiology
Afflicting worldwide nearly 10 million people of all ethnicities per year, venous thromboembolism is a substantial contributor to the global burden of disease.1 The annual incidence of acute venous thromboembolism is 1–2 cases per 1000 population,1, 2, 3 which rises exponentially with age for both men and women,2 and is 4-times higher in high-income than low-income countries.4 The lifetime risk of venous thromboembolism does not differ by sex, but women have a higher risk during the ages of
Pathophysiology
Venous thromboembolism is a multicausal disease believed to be triggered by interactions between multiple provoking factors (panel 1) that can be additive or synergistic. These provoking factors are thought to lead to clinically overt disease when a so-called thrombosis threshold is reached. Some clinical risk factors are strong and might result in venous thromboembolism without the presence of any other risk factors. These strong provoking factors can be transient or persistent. Strong
Diagnosis
The diagnostic approach to suspected venous thromboembolism comprises a sequential work-up combining assessment of clinical pretest probability, D-dimer testing, and imaging. The aim of this diagnostic work-up, which should be done ideally within 24 h of presentation, is to identify patients in whom anticoagulation should be initiated (that is, to confirm venous thromboembolism), and those in whom imaging and anticoagulation can be safely withheld (that is, to exclude venous thromboembolism).
Treatment
Treatment of venous thromboembolism aims to prevent thrombus extension and embolisation, cardiopulmonary collapse, death, recurrent venous thromboembolism, and the risk for long-term complications. Direct oral anticoagulants (DOACs), including the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and the thrombin inhibitor dabigatran represent major advances in the therapeutic management of venous thromboembolism.77 The key aspects of DOACs, including development, pharmacological
Prevention
Appropriate and timely use of measures to prevent venous thromboembolism (hereafter referred to as thromboprophylaxis) in patients at risk for venous thromboembolism are imperative in reducing its global burden. Pharmacological thromboprophylaxis is generally warranted in patient groups in whom the risk of venous thromboembolism is higher than the risk of bleeding, such as patients undergoing major orthopaedic or cancer surgery.146 Individual risk assessment should be done in patient groups in
Future directions
New insights into the pathophysiological mechanisms of venous thrombosis have enhanced our understanding of venous thromboembolism. Advances in diagnostic, therapeutic, and prophylactic strategies have enabled a more individualised approach to patient care, and additional research addressing important clinical questions is ongoing. For example, whether strategies similar to the age-adjusted or pretest probability-adjusted D-dimer can also improve the diagnostic work-up of suspected deep vein
Search strategy and selection criteria
Declaration of interests
TT reports travel and congress fees from Pfizer, and research grant support from the Swiss National Science Foundation (SNSF P2ZHP3_177999) and the CanVECTOR Network. SRK has been part of the advisory board for Pfizer, Sanofi, and Servier. FK and MAR declare no competing interests.
References (164)
- et al.
Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort
Am J Med
(2013) - et al.
The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs
Thromb Res
(2016) - et al.
Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database
Lancet Respir Med
(2020) - et al.
How I treat the postthrombotic syndrome
Blood
(2018) - et al.
Late outcomes of pulmonary embolism: the post-PE syndrome
Thromb Res
(2018) - et al.
Epidemiology of the post-thrombotic syndrome
Thromb Res
(2018) Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome
J Thromb Haemost
(2009)- et al.
Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study
Chest
(2017) - et al.
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH
J Thromb Haemost
(2016) - et al.
Epidemiology of cancer-associated venous thrombosis
Blood
(2013)
Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis
Lancet Haematol
Thrombosis: tangled up in NETs
Blood
Plasma DNA is elevated in patients with deep vein thrombosis
J Vasc Surg Venous Lymphat Disord
Red blood cells in thrombosis
Blood
Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Blood
Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH
J Thromb Haemost
Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH
J Thromb Haemost
American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism
Blood Adv
Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review
Am J Med
Complete venous ultrasound in outpatients with suspected pulmonary embolism
J Thromb Haemost
Diagnostic characteristics of lower limb venous compression ultrasonography in suspected pulmonary embolism: a meta-analysis
J Thromb Haemost
Value of assessment of pretest probability of deep-vein thrombosis in clinical management
Lancet
Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study
Lancet
Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism
J Thromb Haemost
Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review
J Thromb Haemost
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study
Lancet Haematol
Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?
Thromb Res
Diagnosis of suspected recurrent ipsilateral deep vein thrombosis with magnetic resonance direct thrombus imaging
Blood
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report
Chest
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
Blood
Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants
Thromb Res
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis
Blood
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH
J Thromb Haemost
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Lancet Oncol
How I treat cancer-associated venous thromboembolism
Blood
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Blood Adv
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Lancet Haematol
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Blood
Prevalence of confirmed antiphospholipid syndrome in 18–50 years unselected patients with first unprovoked venous thromboembolism
J Thromb Haemost
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis
J Thromb Haemost
Thrombosis: a major contributor to global disease burden
Thromb Res
Epidemiology of venous thromboembolism
Nat Rev Cardiol
Variations in incidence of venous thromboembolism in low-, middle- and high-income countries
Cardiovasc Res
Sex difference in risk of second but not of first venous thrombosis: paradox explained
Circulation
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study
Thromb Haemost
European Union-28: an annualised cost-of-illness model for venous thromboembolism
Thromb Haemost
Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany
Eur Heart J
Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999–2015
JAMA
Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature
Eur Respir J
New insights into the mechanisms of venous thrombosis
J Clin Invest
Cited by (248)
Association between serum uric acid and deep venous thrombosis in European populations: A two-sample Mendelian randomization study
2024, Nutrition, Metabolism and Cardiovascular DiseasesBionanoengineered 2D monoelemental selenene for piezothrombolysis
2024, Biomaterials
- †
Contributed equally